Macular Changes Caused by Occlusion of a Minute Venous Branch

Notting, J. G. A.; Werf, P. J. P. van der

doi:10.1159/000428226

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main reason for the acute visual decrease is macular oedema [11][12][13] and hypoxic damage to retinal tissue due to the impaired circulation of blood. Serious late complications can develop, such as retinal and optic disc neovascularisation, vitreous haemorrhage and neovascular glaucoma.…”

Section: Introductionmentioning

confidence: 99%

Analysis of intravitreal bevacizumab treatment for macular oedema due to retinal vein occlusion

Balla

Zöld

Potor

et al. 2020

European Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: Our aim was to analyse the clinical effect of intravitreal bevacizumab treatment for macular oedema due to central/branch retinal vein occlusion (CRVO/BRVO). The end points were final best-corrected visual acuity (BCVA), BCVA improvement, final central 1-mm macular subfield thickness (CST) and change in CST. Methods: Our study included 34 CRVO and 25 BRVO patients. Patients received intravitreal bevacizumab (IVB) treatment at our department. Our control group consisted of 50 CRVO and 30 BRVO patients, who had not received this treatment because their disease developed before the anti-VEGF treatment became available. For statistical analysis, two-sample t-test, Pearson’s correlation, and ANOVA were used. The level of significance was defined at p < 0.05. Results: With the two-sample t-test we found significant improvement of BCVA in the IVB-treated group (CRVO: 0.171 ± 0.270, p1 = 3.25×10-4; BRVO: 0.215 ± 0.282, p2 = 5.52×10-4). The difference in BCVA improvement was also significant compared to the control group (CRVO: p1 = 3.46×10-4; BRVO: p2 = 0.003). Significant decrease was observed in the CST in the treated group (CRVO: -345.114 ± 280.577, p1 = 6.94×10-9; BRVO: –151.875 ± 174.341, p2 = 1.67×10-4). In case of BRVO patients the final BCVA was significantly better in the treated group (0.617 ± 0.334) compared to the control group (0.406 ± 0.357), p = 0.016. Conclusion: IVB treatment results in significantly better final visual acuity and leads to significantly increased BCVA improvement compared to patients with RVO-induced macular oedema receiving no treatment.

show abstract

Section: Introductionmentioning

confidence: 99%